Wedge Industrial (000534) Q2 2025 earnings summary

Executive summary

• Revenue for H1 2025 reached ¥625.43 million, up 24.40% year-over-year, with net profit attributable to shareholders at ¥119.41 million, up 21.84% year-over-year.

• Main businesses include microecological active bacteria products and high-temperature alloy R&D, manufacturing, and sales.

• The company advanced its dual-engine strategy in pharmaceuticals and high-temperature alloys, with significant R&D and production milestones.

Financial highlights

• Operating income: ¥625.43 million, up 24.40% year-over-year.

• Net profit attributable to shareholders: ¥119.41 million, up 21.84% year-over-year.

• Operating cash flow: ¥6.21 million, up 119.68% year-over-year.

• Basic EPS: ¥0.2397, up 21.27% year-over-year.

• Gross margin for pharmaceutical manufacturing: 90.81%; for high-temperature alloys: 25.86%.

Outlook and guidance

• The company continues to focus on innovation and high-quality development, with ongoing investments in R&D and production capacity.

• New product launches and clinical trials are expected in H2 2025, especially in the microecological and high-temperature alloy segments.